The table below shows Ultragenyx Pharmaceutical Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$136.00M
$159.93M
$166.50M
$139.00M
$139.49M
$147.03M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$187.00M
$216.21M
$164.74M
$166.00M
$170.11M
$161.50M
RARE annual revenue (10-K history)
Ultragenyx Pharmaceutical Inc. reported annual revenue of $673.00M for fiscal year 2025. That is up 20.2% from $560.00M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.00K (FY 2016) to $673.00M. Figures come from the company's audited annual reports as filed with the SEC.